Clinical Efficacy of HiPorfin Photodynamic Therapy for Advanced Obstructive Esophageal Cancer

Abstract

Objective: To explore the clinical efficacy of HiPorfin photodynamic therapy for advanced esophageal cancer and evaluate its impact on survival. Methods: Retrospective analysis of 32 patients with advanced obstructive esophageal cancer at our institution from September 2013 to December 2016. HiPorfin was infused as the photosensitizer at a dose of 5 mg/kg, and after 48 hours, 630-nm laser irradiation was subsequently performed through an optical fiber that passed through the biopsy channel of a flexible endoscope. Results: The effectiveness rate was 78.1% (25/32), and the significant efficacy rate was 56.3% (18/32). The dysphagia score decreased from 3.43 ± 0.73 to 1.79 ± 0.53 ( P < .05). There was no grade 3 or more toxicity. The median overall survival was estimated to be 16 months. Univariate analysis showed higher overall survival with a Karnofsky Performance Status score ≥80 compared with a Karnofsky Performance Status score <80 (hazard ratio: 2.626; 95% CI: 1.091-6.322; P = .024). Overall survival was higher in patients who had received radiation therapy than in patients who did not receive radiation therapy (hazard ratio: 3.574; 95% CI: 1.501-8.510; P = .002). Conclusion: Photodynamic therapy is an effective method for advanced esophageal cancer. The side effects are mild, and the short-term effect is good, especially in the relief of dysphagia. Photodynamic therapy can prolong the survival of patients with advanced esophageal cancer, and the Karnofsky Performance Status score and previous radiation therapy have a significant effect on the overall survival.

Photodynamic therapy improves the clinical efficacy of advanced colorectal cancer and recruits immune cells into the tumor immune microenvironment

“…After three months of follow-up, a complete pathological complete response (pCR) was achieved. The adverse reactions of the enrolled patients during PDT were similar to those reported in the literature (41), mainly transient leukocyte elevation and mild fever, which may be related to inflammatory reactions caused by treatment. Occasionally, patients may have mild abdominal pain, which can be relieved after rest.…”

Effects of combined sintilimab and chemotherapy on progression-free survival and overall survival in osteosarcoma patients with metastasis

“…However, both the chemotherapy drugs used in the AP regimen are associated with multiple adverse Chemotherapy in Treating Metastatic Osteosarcoma reactions, and the combination of sintilimab with this regimen did not increase the adverse reactions of patients with metastatic OS. Previous studies have shown that sintilimab can eliminate smiling lesions, 22 delaying and controlling DP and improving patient survival times and rates. Our results showed significantly higher PFS and OS times in patients treated with sintilimab and the AP regimen than in those treated with the AP regimen alone.…”

“…Previous studies have shown that sintilimab can eliminate smiling lesions, 22 delaying and controlling DP and improving patient survival times and rates. Our results showed significantly higher PFS and OS times in patients treated with sintilimab and the AP regimen than in those treated with the AP regimen alone.…”

Fiber-Optic Biosensors for Cancer Theranostics: From in Vitro to in Vivo

“…The PDT strategy is also effective in targeting advanced cancers. Zeng et al [148] reported the clinical efficacy of PDT in advanced obstructive esophageal cancer, which could prolong the survival of patients with advanced esophageal cancer. Azaïs et al [149] reported the efficacy of intraperitoneal targeted PDT against advanced epithelial ovarian cancer.…”